Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec : reports first quarter 2019 results and provides corporate update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/15/2019 | 09:38am EDT

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today reported financial results and corporate updates for the first quarter of 2019.

STRONG FINANCIAL PERFORMANCE

Group revenues up 27% to EUR 103.8 m (Q1 2018: EUR 81.6 m)

Adjusted Group EBITDA up 114% to EUR 30.0 m (Q1 2018: EUR 14.0 m)

Unpartnered R&D expenses of EUR 8.1 m (Q1 2018: EUR 4.6 m)

Strong strategic liquidity position of EUR 141.6 m despite full repayment of bridge loan facility (total volume: EUR 140 m) drawn in August 2017 in context of Aptuit acquisition (last tranche after period-end)

EXCELLENT OPERATIONAL AND SCIENTIFIC PROGRESS

Multiple new and extended drug discovery and development agreements

Good progress with co-owned, clinical pipeline; multiple important milestone achievements

Consolidation of Basel activities into Toulouse site with transfer of projects to increase overall efficiency of high-throughput screening operations

New licence agreement with Galapagos in fibrosis

Anti-infective research alliances with Helmholtz (HZI) and GARDP

Agreement with The Mark Foundation in immuno-oncology based on Evotec's discovery platform TargetAlloMod

Participation in further financing rounds of Eternygen and Exscientia

Strategic collaboration on precision medicine for colorectal cancer with Indivumed (after period-end)

NOTE

The 2018 and 2019 results are not fully comparable. The difference stems from the acquisition of Evotec ID (Lyon) SAS, effective 01 July 2018. The results from Evotec ID (Lyon) SAS are only included from 01 July 2018 onwards. The accounting policies used to prepare this interim information are the same as those used to prepare the audited consolidated financial statements for the year ended 31 December 2018, except for the adoption of IFRS 16 as of 01 January 2019. From 01 January 2019 onwards, Evotec applies IFRS 16.

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact:

Tel: +49. (0)40.560 81-255

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC SE
08:45aEVOTEC : Sensyne health, the university of oxford, osi, and oui create new bridg..
AQ
06/24EVOTEC : Sensyne health, the university of oxford, osi, and oui create new bridg..
EQ
06/20EVOTEC : Resolutions of the Annual General Meeting 2019 of Evotec SE
AQ
06/19EVOTEC : Resolutions of the annual general meeting 2019 of evotec se
EQ
06/13EVOTEC : bags US$23.8m to fight tuberculosis
AQ
06/12EVOTEC : bags $23.8m to fight tuberculosis
AQ
06/11EVOTEC : receives $ 23.8 m grant to join the global fight against tuberculosis
AQ
06/10EVOTEC : Receives $ 23.8 m grant to join the global fight against tuberculosis
EQ
06/06EVOTEC : and Celgene further expand iPSC collaboration including new cell type
AQ
06/05EVOTEC : And celgene further expand ipsc collaboration including new cell type
EQ
More news
Financials (€)
Sales 2019 417 M
EBIT 2019 73,7 M
Net income 2019 53,5 M
Finance 2019 3,00 M
Yield 2019 -
P/E ratio 2019 67,08
P/E ratio 2020 65,60
EV / Sales 2019 8,82x
EV / Sales 2020 7,66x
Capitalization 3 686 M
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 26,9 €
Spread / Average Target 9,1%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE41.66%3 664
IQVIA HOLDINGS INC35.52%26 223
LONZA GROUP28.39%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION36.69%17 061
EXACT SCIENCES CORPORATION80.30%13 037